muscle loss on glp 1 Weight with GLP-1 medicines does not result in a disproportionate loss of mass or function in obese mice and humans GLP-1 and Muscle Loss: Semaglutide,

Foundayo (orforglipron) received FDA approval in April 2026, and oral Wegovy tablets received FDA-approval in December 2025

Dehydration builds faster than people expect Reduced appetite can mean less fluid intake

Coverage for weight loss is a different story: only 13 states cover obesity-indicated GLP-1s as of January 2026, and that number has been shrinking as states face budget pressure

GLP-1 Probiotic PRO is versatile and can be used in various ways

The cloud hanging over the entire class right now is hepatotoxicity

Yohimbine has been shown to cause changes in human heart cells, including disrupted sodium and calcium signaling and longer action potentials